



# Vertical Transmission in Infants Born to Women with HIV on Antiretroviral Treatment

Kim Anderson<sup>1</sup>, Emma Kalk<sup>1</sup>, Alexa Heekes<sup>2</sup>, Florence Phelanyane<sup>2</sup>, Nisha Jacob<sup>3</sup>, Andrew Boule<sup>1,2,3</sup>, Ushma Mehta<sup>1</sup>, Gayathri Sridhar<sup>4</sup>, Leigh Ragone<sup>4</sup>, Vani Vannappagari<sup>4,5</sup>, Mary-Ann Davies<sup>1,2,3</sup>

<sup>1</sup>Centre for Infectious Disease Epidemiology and Research, School of Public Health, Faculty of Health Sciences, University of Cape Town, South Africa, <sup>2</sup>Health Intelligence, Western Cape Department of Health, Cape Town, South Africa,

<sup>3</sup>Division of Public Health Medicine, School of Public Health, University of Cape Town, South Africa, <sup>4</sup>ViiV Healthcare, Durham, NC, USA, <sup>5</sup>Department of Epidemiology, Gillings School of Public Health, University of North Carolina, Chapel Hill, NC, USA


## BACKGROUND

- Monitoring of mother-infant pairs with HIV exposure is needed to assess effectiveness of vertical transmission prevention programmes and progress towards elimination of vertical transmission.

## METHODS

- We used routinely-collected data on infants with HIV exposure, born May 2018 – April 2021 to mothers diagnosed with HIV prior to delivery, in the Western Cape, South Africa, with follow-up through mid-August 2022.
- We assessed proportion of infants with HIV exposure who were diagnosed with HIV at birth ( $\leq 7$  days), 10 weeks ( $>1$  to 14 weeks) and  $>14$  weeks as proxies for intrauterine, intrapartum/early breastfeeding and late breastfeeding transmission, respectively.
- To calculate proportions, the denominator used was infants not previously testing positive and with an available test at each interval.

**Figure 1: All infant HIV tests performed, by week of life**



Note: Includes positive, negative and repeat tests; includes HIV-PCRs, ELISA and Rapid assays; but excludes duplicate results from the same day for the same infant. Peaks in testing align with programmatic testing at birth, 10 weeks and 6 months, although 6-month PCR testing was only introduced in year 3, prior to which 9-month Rapid screening was conducted. Rapid tests are not routinely captured electronically and may be missing from the data.

At delivery, mothers had  
VL<100: 74%  
CD4 $\geq$ 350: 62%

At birth, 10 weeks &  $>14$  weeks,  
0.8%, 0.4% & 1.1%  
of infants tested positive

## RESULTS

### Mothers

- 68% of mothers started antiretroviral treatment (ART) before pregnancy (although 5% of them had no ART during pregnancy); 27% started during pregnancy; and, at delivery, 5% had no prior ART recorded.
- 90% of mothers received any ART during pregnancy; 86% received any ART in the year after delivery.
- Most pregnancy regimens included non-nucleoside reverse transcriptase inhibitors (84%); 11% integrase strand transfer inhibitors and 5% protease inhibitors.
- 43% of mothers had viral load (VL) results at delivery, of whom 74% had VL  $<100$  copies/ml.
- 68% of mothers had CD4 count results during pregnancy, of whom 62% had CD4 count  $\geq 350$  cells/ $\mu$ l.
- Of mothers whose infants were diagnosed with HIV: 94% had started ART before or during pregnancy; 49% had VL results at delivery, of whom 16% had VL  $<100$  copies/ml.

### Infants

- Among 49 824 HIV-exposed infants, 925 (2%) were diagnosed with HIV.
- HIV-PCR results were available for 83% of eligible infants at birth, 67% at 10 weeks and 48% at  $>14$  weeks of age.
- Among eligible infants who were tested at the different timepoints, 0.8% were positive at birth, 0.4% at 10 weeks and 1.1% at  $>14$  weeks. Of infants diagnosed with HIV, 47% were identified at birth, 18% at 10 weeks and 35% at  $>14$  weeks of age.
- Of infants who first tested positive at 10 weeks, 68% had previous negative birth tests (suggesting intrapartum/early breastfeeding transmission) and 52% who first tested positive at  $>14$  weeks had previous negative tests at 1-14 weeks (suggesting late breastfeeding transmission).
- Overall infant mortality was 1% ( $n=720/49824$ ) but was 4% ( $n=41/925$ ) among infants with HIV.
- An additional 742 infants were diagnosed with HIV in the study period but were excluded from analysis as maternal evidence of HIV was after delivery ( $n=341$ ) or no linked maternal data was available ( $n=401$ ).

## CONCLUSIONS

- Despite high maternal ART coverage, ongoing vertical transmission is a concern, with a substantial proportion attributable to breastfeeding transmission.
- Interventions to improve maternal viral suppression and reduce vertical transmission in pregnancy and breastfeeding are needed to achieve an HIV-free generation.


## ADDITIONAL INFORMATION

**Author contact information:** kim.anderson@uct.ac.za

**Acknowledgements:** We acknowledge the infants included in the study, their mothers, clinicians and service providers. We thank the Provincial Health Data Centre for their assistance with data extraction.

**Funding:** ViiV Healthcare

**Figure 2: Vital status and HIV status at different time points for infants with HIV exposure**





**This content was acquired following an unsolicited medical information enquiry by a healthcare professional. Always consult the product information for your country, before prescribing a ViiV medicine. ViiV does not recommend the use of our medicines outside the terms of their licence. In some cases, the scientific information requested and downloaded may relate to the use of our medicine(s) outside of their license.**